Prescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Pre-Extraction Phase, Extraction Phase, Post-Extraction Phase.
- Who it may be relevant to
- Registry conditions: Dementia. Basic parameters: from 21 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prescribing Trends and Associated Outcomes of Antiepileptic Drugs and Other Psychoactive Medications in US Nursing Homes Surrounding the COVID-19 Pandemic
Overview
Since the "National Partnership to Improve Dementia Care" debuted in 2012, almost all long-stay psychoactive prescribing has been graded by CMS, which has correlated to decreased use. However, some national data suggest that while these psychoactive medications are being used less, prescriptions of mood-stabilizing antiepileptic drugs (AEDs) have increased. Unlike all other psychoactive medications, AEDs prescribed in nursing homes are not mandatorily reported to CMS or graded in a quality-measure.
Detailed description
Pilot studies from Virginia suggest increases in AEDs are concentrated entirely in dementia patients with no diagnosis of epilepsy and as a purposeful unmonitored alternative to antipsychotics. AEDs are not FDA approved for dementia symptoms, have weak efficacy evidence, and convey serious risk. Increasingly it seems likely that the Partnership's debut was an inflection point where the trend towards unmonitored alternative drugs for dementia symptoms sharply increased. Early Commonwealth data hints that the COVID pandemic represents a second critical point of inflection where the existing transition towards non-superior but unreported drugs is again rapidly accelerating. All outcomes associated with this evolving prescribing phenomenon remain unknown. That said, pilot data suggests that harms may be increasing without benefit, a development with relevance to all invested in improving dementia care including patients, caregivers, and policy makers.
Interventions
- Other Pre-Extraction Phase
This intervention requires the following procedures: Submitting data use agreement, MDS request defined and developed, Part D request, CMS public use file request defines and develop questionnaire - Other Extraction Phase
Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire - Other Post-Extraction Phase
Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation
Primary outcome measures
- Quarterly rate of use and mean dose of AEDs in US nursing homes [Time frame: The years 2009 to 2021]
Secondary outcome measures (2)
- Quarterly rate of use of AEDs in US nursing homes for long-stay residents [Time frame: The years 2009 to 2012]
- Quarterly rate of adverse health events among US nursing home residents prescribed or not prescribed AEDs [Time frame: The years 2009 to 2021]
Eligibility criteria
Inclusion criteria
- All long-stay nursing home residents will be included. We define long-stay nursing home residents as all individuals residing in a nursing facility place of service for more than 100 days
- All nursing home clinicians prescribing psychoactive drugs will be included.
Exclusion criteria
- Limited to nursing home residents with continuous fee-for-service or Medicare Advantage plans as well as continuous Part D coverage.
- Residents without continuous fee-for-service insurance (less than 3 percent of nursing home population) will be excluded.
- Less than 0.2% of nursing home residents are children; still, this study will be restricted to those > 21 years of age.
- Nursing home residents who are discharged before the end of the quarterly study periods will also be excluded.
- Residents with discharges for acute hospitalizations followed by facility reentry on the same record will not be excluded.
- Non-prescribing clinicians and clinicians that do not prescribe psychoactive medications will be excluded.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Virginia Commonwealth University — Richmond
Identifiers
NCT: NCT06095284 · HM20025382 · R01AG074358